🇺🇸 FDA

Drug profile · INN

mavacamten

CAMZYOS

FDA: approved EMA: approved TGA: approved PMDA: approved C01EB
US status
approved
Patents linked
0
News articles
0

Quick answer

mavacamten (CAMZYOS) is an FDA-listed pharmaceutical active ingredient. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN mavacamten
Brand CAMZYOS
Route ORAL
Formulation CAPSULE
ATC code C01EB
Originator Bristol-Myers Squibb Australia Pty Ltd

Frequently asked questions

What is mavacamten?

mavacamten (CAMZYOS) is an FDA-listed pharmaceutical active ingredient. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for mavacamten?

CAMZYOS is a marketed brand name for mavacamten. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of mavacamten?

mavacamten has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.